市場調查報告書
商品編碼
1450999
2024-2032 年按產品、應用、配方和地區分類的止血劑市場報告Hemostats Market Report by Product, Application, Formulation, and Region 2024-2032 |
2023年,全球止血劑市場規模達到35億美元。展望未來, IMARC Group預計到2032年市場規模將達到58億美元,2024-2032年複合年成長率(CAGR)為5.73%。外科手術的增加、技術的進步、醫療基礎設施的擴張、醫療保健專業人員意識的提高以及人口老化的加劇是推動市場的一些主要因素。
止血鉗是指在外科手術或傷口治療期間透過夾緊血管或組織來控制出血的醫療器械。它們通常由一對鉸接的剪刀狀手柄組成,工作端帶有鋸齒狀鉗口。當擠壓手柄時,鉗口閉合,牢牢抓住組織或血管。這可以防止血液流動並有利於精確操作或縫合。止血劑有各種尺寸和設計,使其成為醫療保健環境中的多功能工具。它們在確保手術場無血、降低失血過多的風險以及實現有效的醫療程序方面發揮著至關重要的作用。
外科手術(包括複雜手術、微創手術和創傷病例)發生率的上升是推動止血劑和器械需求的主要因素。此外,隨著全球人口持續老化,心血管疾病和癌症等需要手術介入的慢性疾病的盛行率不斷增加,有助於市場擴張。同時,醫療技術的不斷進步促進了創新止血產品的開發,其功效和安全性得到提高,進一步推動了市場成長。此外,醫療保健專業人員越來越意識到有效止血對於減少併發症和改善患者預後的重要性,這推動了止血劑的採用。此外,隨著外科護理的普及,新興市場醫療保健基礎設施的擴張,加上醫療保健支出的增加,正在促進止血劑市場的成長。
增加外科手術
全球外科手術數量的不斷增加是止血劑市場的重要動力。手術介入對於治療各種疾病至關重要,從闌尾切除術等常規手術到器官移植等複雜手術。隨著全球人口持續成長和老化,心血管疾病、癌症和骨科問題等慢性疾病的盛行率也在上升。這導致對外科手術以及止血劑和器械的需求不斷增加。止血劑在這些手術中對於控制出血、降低併發症風險和改善患者預後至關重要。
持續的技術進步
醫療技術的進步在止血劑市場的成長中發揮了關鍵作用。這些創新促進了更有效、更安全的止血產品的開發。例如,新型止血劑通常採用生物相容性和生物可吸收材料,降低不良反應的風險。此外,一些止血劑的作用速度更快,從而節省了寶貴的手術時間。此外,微創手術等外科技術的進步增加了對這些手術量身定做的專用止血工具的需求。技術創新持續推動產品開發,提升整體市場。
新興市場的醫療基礎設施擴張
新興市場,特別是亞洲、拉丁美洲和非洲,醫療基礎設施和支出正在經歷顯著成長。這種擴張是由城市化、可支配收入增加以及政府為改善醫療保健所採取的更多措施所推動的。隨著醫療保健設施變得更加便利,在這些地區進行的外科手術數量正在增加。因此,對支持這些手術的止血劑和儀器的需求不斷成長。醫療保健基礎設施的擴張不僅擴大了市場的地理範圍,而且還促進了本地和國際止血劑製造商之間的夥伴關係和合作機會。
The global hemostats market size reached US$ 3.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.8 Billion by 2032, exhibiting a growth rate (CAGR) of 5.73% during 2024-2032. The rising surgical procedures, technological advancements, expansion of healthcare infrastructure, increasing awareness among healthcare professionals, and a growing aging population are some of the major factors propelling the market.
The rising incidence of surgical procedures, including complex surgeries, minimally invasive procedures, and trauma cases, represents the prime factor fueling the demand for hemostatic agents and instruments. Moreover, as the global population continues to age, the prevalence of chronic diseases necessitating surgical interventions, such as cardiovascular diseases and cancer, is increasing, aiding in market expansion. Concurrent with this, ongoing advancements in medical technology have led to the development of innovative hemostatic products with improved efficacy and safety profiles, further propelling market growth. Additionally, the growing awareness among healthcare professionals about the importance of effective hemostasis to reduce complications and enhance patient outcomes has driven the adoption of hemostats. Furthermore, the expansion of healthcare infrastructure in emerging markets, coupled with increasing healthcare expenditure, is contributing to the growth of the hemostats market as access to surgical care becomes more widespread.
Increasing surgical procedures
The growing number of surgical procedures worldwide is a significant driver for the hemostats market. Surgical interventions are essential for treating various medical conditions, from routine procedures like appendectomies to complex surgeries like organ transplants. As the global population continues to grow and age, the prevalence of chronic diseases such as cardiovascular diseases, cancer, and orthopedic issues is also on the rise. This has led to an increasing demand for surgical interventions, and consequently, hemostatic agents and instruments. Hemostats are crucial in these procedures to control bleeding, reduce the risk of complications, and improve patient outcomes.
Ongoing technological advancements
Advances in medical technology have played a pivotal role in the growth of the hemostats market. These innovations have led to the development of more effective and safer hemostatic products. For example, newer hemostats often incorporate biocompatible and bioabsorbable materials, reducing the risk of adverse reactions. Additionally, some hemostatic agents are engineered to work more rapidly, thus saving valuable surgical time. Moreover, advancements in surgical techniques, such as minimally invasive surgery, have increased the demand for specialized hemostatic tools tailored to these procedures. Technological innovations continue to drive product development, enhancing the overall market.
Healthcare infrastructure expansion in emerging markets
Emerging markets, particularly in Asia, Latin America, and Africa, are experiencing significant growth in healthcare infrastructure and expenditure. This expansion is driven by urbanization, rising disposable incomes, and increased government initiatives to improve healthcare access. As healthcare facilities become more accessible, the number of surgical procedures performed in these regions is on the rise. Consequently, there is a growing demand for hemostatic agents and instruments to support these surgeries. The expansion of healthcare infrastructure not only increases the market's geographical reach but also fosters opportunities for partnerships and collaborations between local and international hemostat manufacturers.
IMARC Group provides an analysis of the key trends in each segment of the global hemostats market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, application, and formulation.
Thrombin Based
Combination Based
Oxidized Regenerated Cellulose Based
Gelatin Based
Collagen Based
Thrombin based dominates the market
The report has provided a detailed breakup and analysis of the market based on the product. This includes thrombin based, combination based, oxidized regenerated cellulose based, gelatin based, and collagen based. According to the report, thrombin based represented the largest segment.
The demand for thrombin based hemostats is being propelled by their rapid action and versatility in managing bleeding in various medical scenarios. Thrombin is a naturally occurring enzyme that plays a crucial role in the blood clotting process. Thrombin-based hemostats offer a targeted and rapid solution for achieving hemostasis, making them particularly valuable in situations where time is critical, such as emergency surgeries and trauma cases. Furthermore, their ability to work independently of the body's clotting mechanisms makes them an attractive option, and their compatibility with other hemostatic agents enhances their versatility in surgical applications, further driving their demand in the healthcare industry.
Orthopedic Surgery
General Surgery
Neurological Surgery
Cardiovascular Surgery
Reconstructive Surgery
Gynecological Surgery
Others
General surgery holds the largest share in the market
A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes orthopedic, general, neurological, cardiovascular, reconstructive, gynecological, and other surgeries. According to the report, general surgery accounted for the largest market share.
The increasing complexity and diversity of surgical procedures represent one of the main factors impelling the need for hemostats in general surgery applications. General surgery encompasses a wide range of operations, from abdominal surgeries to vascular procedures, each posing unique challenges in achieving effective hemostasis. Surgeons are increasingly relying on hemostatic agents and instruments to minimize bleeding, reduce operating time, and enhance patient outcomes. As surgical techniques advance, minimally invasive procedures become more common, necessitating specialized hemostatic tools. Moreover, the expanding aging population with comorbidities requires more surgical interventions, further fueling the demand for reliable and versatile hemostats in general surgery applications.
Matrix and Gel Hemostats
Sheet and Pad Hemostats
Sponge Hemostats
Powder Hemostats
Matrix and gel hemostats dominate the market
The report has provided a detailed breakup and analysis of the market based on the formulation. This includes matrix and gel, sheet and pad, sponge, and powder hemostats. According to the report, matrix and gel hemostats represented the largest segment.
The demand for matrix and gel hemostats is driven by their unique characteristics, such as ease of application and versatility in various medical settings. These hemostatic products offer a user-friendly approach to achieving hemostasis, especially in situations where precise control is essential, such as neurosurgery and ophthalmic procedures. Matrix and gel hemostats conform to irregular wound shapes and adhere well to tissues, ensuring effective sealing of bleeding sites. Apart from this, they often have a resorbable nature, reducing the risk of adverse reactions and minimizing the need for postoperative removal, making them increasingly favored by surgeons and healthcare professionals in diverse clinical applications.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest hemostats market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
The North American hemostats market is experiencing significant growth due to the region's aging population driving a higher prevalence of chronic diseases, resulting in an increased demand for surgical interventions, which in turn necessitates the use of hemostatic agents and instruments. Concurrent with this, the well-established healthcare infrastructure in North America, coupled with high healthcare expenditure, allows for extensive adoption of advanced hemostatic technologies and products. Additionally, ongoing technological advancements in the healthcare sector, particularly in the United States, are contributing to the development of innovative hemostatic solutions that are highly sought after by healthcare providers. Furthermore, the region's regulatory environment and stringent quality standards ensure the availability of safe and effective hemostats, further boosting market growth. Apart from this, the rising awareness among healthcare professionals regarding the importance of efficient hemostasis to minimize complications is propelling the North America hemostats market forward.
The global hemostats market is characterized by intense competition, driven by a multitude of established and emerging players striving to gain a competitive edge. Key market participants include leading healthcare companies that have a strong global presence and offer a wide range of hemostatic products. These industry giants engage in extensive research and development efforts to introduce innovative hemostats and expand their product portfolios. Additionally, smaller, niche-focused companies are gaining prominence by offering specialized hemostatic solutions. Collaborations, partnerships, and mergers and acquisitions are common strategies in this dynamic landscape, aimed at strengthening market positions and enhancing product offerings. The competitive rivalry is further fueled by the increasing demand for minimally invasive surgery and the ongoing quest to develop hemostatic agents with enhanced safety profiles, driving continuous innovation and competitiveness in the global hemostats market.
Arch Therapeutics Inc.
Baxter International Inc.
B. Braun Melsungen Aktiengesell
C. R. Bard Inc.
GELITA MEDICAL GmbH
Integra LifeSciences Corporation
Johnson & Johnson
Pfizer Inc.
Stryker Corporation
Teleflex Incorporated
Z-Medica LLC
In July 2023, Baxter International Inc. announced the launch of PERCLOT Absorbable Hemostatic Powder in the U.S. PERCLOT is a passive, absorbable hemostatic powder that is ready to use and designed for patients with intact coagulation to address mild bleeding.
In April 2023, Arch Therapeutics, Inc. a marketer and developer of novel self-assembling wound care and biosurgical products, unveiled its AC5(R) Advanced Wound System ("AC5") at the Symposium on Advanced Wound Care. .